9 results about "Vaccine therapy" patented technology

This invention discloses an antibody-engineered bone marrow stromal cell and its applications, belonging to the field of biomedical technology. Using bone marrow stromal cells as a biological carrier, this invention externally modifies them with immune checkpoint antibodies to form an antibody-coated engineered cell preparation, thereby achieving targeted and precise mitochondrial delivery of exhausted T cells. This cell preparation can be used in combination with other immunotherapies that can induce T cell exhaustion, such as tumor immunotherapies and CAR-T therapy, to help enhance their anti-tumor efficacy and duration of effect.

The invention discloses antibody coupled lipid nanoparticles for targeted heart delivery of mRNA (messenger Ribonucleic Acid) as well as a preparation method and application of the antibody coupled lipid nanoparticles, and belongs to the field of biological medicine pharmacy. The antibody-coupled lipid nanoparticles are obtained by inserting phospholipid coupled with a Myh7 antibody into lipid nanoparticles wrapping mRNA (messenger ribonucleic acid); the mass ratio of the phospholipid coupled with the Myh7 antibody to the lipid nanoparticles wrapping the mRNA is (5-10): 1. According to the present invention, the Myh7 antibody is coupled with the lipid nanoparticles, such that the delivery efficiency of the lipid nanoparticles to the heart is substantially enhanced, the delivery efficiency at the myocardial injury position is particularly efficient, the mRNA activity is retained, and the efficient approach is provided for the preparation of the mRNA drug by using the lipid nanoparticles or the treatment of the heart-related diseases by using the vaccine therapy.

A vaccine for the treatment or prevention of Pseudomonas aeruginosa infection in a subject. A composition comprising one or more immunogens is provided. The composition is for use in vaccine therapy to treat or prevent P. aeruginosa infection in subject.

Binding proteins and high affinity recombinant T cell receptors (TCRs) specific for novel Islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) epitope presented by the class II DRB4 neoantigens are provided herein. Compositions and recombinant host cells encoding and / or expressing the binding proteins and / or high affinity recombinant TCRs are also provided. The compositions and recombinant host cells may be used to treat a subject having Type 1 diabetes, wherein an IGRP neoantigen is a therapeutic target, or an indication wherein IGRP neoantigen is a therapeutic target. Related vaccines, vaccine therapies, and vaccination regimens are also provided.

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccination strategy.

The invention relates to the technical field of biological medicines, and particularly discloses a neoantigen epitope peptide fragment presented based on MHC-II, a vaccine, a pharmaceutical composition and application. Wherein the epitope key sequence of the peptide fragment is MVMGVLDQAFDVLVL, and the epitope key sequence is MVMGVLDQAFDVLVL; a KVMGVLDQAFDVLVL is used as a model; kVMGVLKQAFDVLVL is used as a model; kVLGVLKQAFDVLVL is used as a model; and KVKGVLKQAFDVLVL can be selected from any one of KVKGVLKQAFDVLVL. The new antigen with the epitope peptide fragment can be recognized by CD4 + T cells, so that the CD4 + T cells can provide necessary auxiliary signals to enhance the immune response of the CD8 + T cells, and finally the CD8 + T cells are helped to kill tumor cells such as pancreatic cancer. The discovery of the peptide fragment can be beneficial to popularization and application of vaccine therapy in the field of tumor diseases such as pancreatic cancer.

A Klebsiella pneumoniae vaccine. A composition comprising one or more immunogens is provided. The composition is for use in vaccine therapy to treat or prevent K. pneumoniae infection in subject.

A liposome vaccine composition for inducing an anti-A [beta] immune response in a human subject without causing a severe adverse event, comprising: a beta-amyloid (A [beta])-derived peptide antigen exhibited on the surface of a liposome, said peptide antigen comprising, essentially consisting of, or consisting of, the amino acids 1 to 15 of A [beta]; a peptide comprising a universal T cell epitope; and an adjuvant comprising monophosphoryl lipid A (MPLA). The beta-amyloid (A beta)-derived peptide antigen (SEQ ID NO: 1) is administered in an amount of 300 to 2000 [mu] g. The liposome vaccine composition is administered intramuscularly or subcutaneously.